Search Results

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Cellular Origins, a TTP Company focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies, and the Cell and Gene Therapy Catapult, an independent innovation and technology organisation specialising in the advancement of the cell and gene therapy industry, announced a collaboration to demonstrate universal automation of CGT manufacturing.

Coeptis Therapeutics Holdings, Inc. announced today that the Company has been selected for an oral presentation of the abstract titled Developing A First-In-Class Universal Allogeneic Snap-Car NK Cell Therapy at the International Society for Cell & Gene Therapy 2024, being held May 28th to June 1st in Vancouver, Canada.

INTASYL compounds also improve the functionality and outcomes of adoptive cell therapies such as NK, TIL and CAR-T

Q&A: Development Scientist at AGC Biologics Sara Morlacchi analyzes the growth of the cell therapy industry and barriers for cost and accessibility.

BioLife Solutions, Inc., a leading supplier of bioproduction tools and services for the cell and gene therapy and broader biopharma markets, announced the introduction of the CryoCase, an addition to its CellSeal product line.

Evergreen Theragnostics, Inc. today announced that they have entered into a collaboration and licensing-agreement with the Medical University of Innsbruck (MUI), a leading European research institution to advance the development of novel radiopharmaceuticals.

Actinium Pharmaceuticals, Inc. announced it will host a KOL call on Monday, May 20, 2024, at 8:00 AM ET to provide updates and highlight its recently announced clinical trial to study Iomab-ACT with a leading FDA approved CAR-T cell therapy at the University of Texas Southwestern.